Dataset Information

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

ABSTRACT: Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients' perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care professionals and the relationship to the treating physician.In this report, we considered physicians' and patients' evaluation of satisfaction with interferon beta-1b treatment efficacy for assessing the congruence in ratings. Data were queried in a study conducted between 2009 and 2013.After 6 months of therapy, >?80 % of the patients and physicians (N?=?445) showed high degrees of satisfaction regarding interferon beta-1b treatment, with only few physicians and patients (?2.0 %) rating "not satisfied". The proportion of patients rating with the same category as their physicians was similar after 6 months (47 % congruence) and at the 24 months/study end visit (49 %). Discrepancies between ratings were observed with respect to study end: for patients with premature study end, more patients and physicians rated being not satisfied with the therapy, accompanied by a considerably lower congruence of 33 % compared to 54 % for patients receiving the therapy for at least 2 years and completing the study regularly.Regular communication between physicians and patients about their perception of therapy might improve alignment of treatment evaluation and could result in increased therapy persistence. In addition, patients' willingness to perform a long-term therapy?-?even in the absence of disease symptoms?-?might be promoted by repeated exchange between health care providers and patients with regard to realistic treatment expectations.ClinicalTrials.gov NCT00902135 (registered May 13, 2009).

SUBMITTER: Zettl UK

PROVIDER: S-EPMC5031257 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Zettl Uwe Klaus UK Bauer-Steinhusen Ulrike U Glaser Thomas T Hechenbichler Klaus K Hecker Michael M

BMC neurology 20160921 1

<h4>Background</h4>Due to the preventive nature of disease-modifying therapies for multiple sclerosis, treatment success particularly depends on adherence to therapeutic regimens and patients' perception of treatment efficacy. The latter is strongly influenced by the confidence in the involved health care professionals and the relationship to the treating physician.<h4>Methods</h4>In this report, we considered physicians' and patients' evaluation of satisfaction with interferon beta-1b treatment ...[more]

PMID: 27653529

Similar Datasets

Project description:IntroductionMultiple sclerosis (MS) typically requires life-long management with disease-modifying therapies (DMTs). Many DMTs require regular self-injection, and can be associated with injection site reactions, pain, and needle/injection phobia-but these can be addressed by improvements in autoinjector design. The aim of this study was to investigate patient satisfaction and preference for BETACONNECT™ (Bayer Pharma AG), a novel interferon beta-1b autoinjector.MethodsPatients in Germany performing self-injections using BETACONNECT took part in the study. Data were collected through an online 15-min structured survey. Participants rated their experience with BETACONNECT on a 6-point scale and those satisfied with BETACONNECT were asked to describe the reason using a free-text box.ResultsOne-hundred and eighteen patients with MS completed the survey. Ninety percent preferred BETACONNECT to their previous injection method (only 4% previously used manual injections, so most had previously used other autoinjectors). Ninety-two percent were very confident/confident in their ability to perform an injection using BETACONNECT. The most common free-text responses to "Why are you satisfied with the BETACONNECT™ autoinjector?" were ease of use (46%), less irritation/pain at the injection site (33%), and smoother injections (24%). Features considered most useful were automated injections (98%), adjustable injection speed (98%), and adjustable injection depth (98%). Ninety-seven percent thought it was easy to know when an injection was complete and 95% agreed/strongly agreed it was easy to learn to use the autoinjector. Seventy-three percent agreed that the quietness and effortlessness of the BETACONNECT reduced their level of injection anxiety, 92% that its size and shape makes it easy to handle during injections, and 67% that it decreases injection site pain. Eighty percent of those using the reminder function thought they were less likely to miss an injection.ConclusionPatients with MS self-injecting interferon beta-1b expressed a high level of satisfaction and preference for BETACONNECT. Thus, BETACONNECT represents a valid option to improve patients' overall injection experience.FundingBayer HealthCare Pharmaceuticals.

Dataset Information

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Publications

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets